ArticleSurgery today2013
High expression of cancer stem cell markers in cholangiolocellular carcinoma.
Article in Surgery today, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Long Non-Coding RNAs in Biliary Tract Cancer-An Up-to-Date Review.Journal of clinical medicine · 2020Review
- Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications.International journal of molecular sciences · 2019Review
- Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma.Nature communications · 2018Article
- Small cholangiolocellular carcinoma that was difficult to distinguish from cholangiocellular carcinoma: a case report.Surgical case reports · 2017Article
- Biliary tract cancer stem cells - translational options and challenges.World journal of gastroenterology · 2017Review
- Claudins-4 and -7 might be valuable markers to distinguish hepatocellular carcinoma from cholangiocarcinoma.Virchows Archiv : an international journal of pathology · 2016Article
- Full-length LGR5-positive cells have chemoresistant characteristics in colorectal cancer.British journal of cancer · 2016Article
- The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells.Oncotarget · 2016Article
- Improved surgical outcomes for hilar cholangiocarcinoma: changes in surgical procedures and related outcomes based on 40 years of experience at a single institution.Surgery today · 2016Article
- The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells.BMC complementary and alternative medicine · 2015Article
- Giant Cholangiolocellular Carcinoma With Early Recurrence That Was Difficult to Distinguish From Cholangiocellular Carcinoma: Report of a Case.International surgery · 2015Article
- BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer.Cancer science · 2015Article
- RFPL4A increases the G1 population and decreases sensitivity to chemotherapy in human colorectal cancer cells.The Journal of biological chemistry · 2015Article
- Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma.Oncoscience · 2015Review
- Role of liver stem cells in hepatocarcinogenesis.World journal of stem cells · 2014Review
- 3D Silk Fibroin-Gelatin/Hyaluronic Acid/Heparan Sulfate Scaffold Enhances Expression of Stemness and EMT Markers in Cholangiocarcinoma.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCholangiolocellular carcinoma (CLC) is an extremely rare malignant liver tumor. It is thought to originate from the ductules and/or canals of Hering, where hepatic stem cells (HpSC) are located, but there are few reports on cancer stem cell markers in CLC. Thus, we evaluated the significance of cancer stem cell markers, including CD133, CD44, and EpCAM, in CLC.
methodsThe subjects of this study were three patients with CLC and one patient with an intermediate type of combined hepatocellular cholangiocarcinoma (CHC). The cancer cell markers, CK7, CK19, and EMA, were evaluated immunohistochemically.
resultsHistological examination of the CLC revealed morphologically cholangiolar features and immunohistochemical examination revealed positivity for CD133, CD44, and EpCAM. On the other hand, in the intermediate type of CHC, only CD44 was positive, whereas CD133 and EpCAM were negative.
conclusionCLC may have stronger features derived from HpSCs than an intermediate type of CHC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.